Is XGN or PIII more profitable?

P3 Health Partners has a net margin of -6.55% compared to Exagen's net margin of -26.61%. P3 Health Partners' return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% P3 Health Partners -6.55% N/A -16.40%

Is PIII or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to P3 Health Partners' net margin of -6.55%. P3 Health Partners' return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets P3 Health Partners -6.55% N/A -16.40% LifeMD 0.10% -168.23% -31.27%

Do analysts rate PIII or JYNT?

P3 Health Partners currently has a consensus price target of $17.00, suggesting a potential upside of 167.30%. Given P3 Health Partners' stronger consensus rating and higher probable upside, equities research analysts plainly believe P3 Health Partners is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score P3 Health Partners 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is PIII or JYNT more profitable?

Joint has a net margin of 6.49% compared to P3 Health Partners' net margin of -6.55%. Joint's return on equity of 12.02% beat P3 Health Partners' return on equity. Company Net Margins Return on Equity Return on Assets P3 Health Partners -6.55% N/A -16.40% Joint 6.49% 12.02% 3.47%

Is PIII or PARK more profitable?

Park Dental Partners has a net margin of 0.00% compared to P3 Health Partners' net margin of -6.55%. Company Net Margins Return on Equity Return on Assets P3 Health Partners -6.55% N/A -16.40% Park Dental Partners N/A N/A N/A

P3 Health Partners (PIII) Competitors

$6.36 +0.09 (+1.44%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$6.34 -0.03 (-0.39%)

As of 10/2/2026 07:30 PM Eastern

Compare

PIII vs. XGN, LFMD, JYNT, PARK, and ACH

Should you buy P3 Health Partners stock or one of its competitors? P3 Health Partners's main competitors and comparable companies include Exagen (XGN), LifeMD (LFMD), Joint (JYNT), Park Dental Partners (PARK), and Accendra Health (ACH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does P3 Health Partners compare to Exagen?

Exagen (NASDAQ:XGN) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, Exagen had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 1 mentions for Exagen and 0 mentions for P3 Health Partners. Exagen's average media sentiment score of 0.00 equaled P3 Health Partners'average media sentiment score.

Company	Overall Sentiment
Exagen	Neutral
P3 Health Partners	Neutral

75.3% of Exagen shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 10.9% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Exagen currently has a consensus target price of $9.63, indicating a potential upside of 17.81%. P3 Health Partners has a consensus target price of $17.00, indicating a potential upside of 167.30%. Given P3 Health Partners' higher possible upside, analysts plainly believe P3 Health Partners is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

P3 Health Partners has a net margin of -6.55% compared to Exagen's net margin of -26.61%. P3 Health Partners' return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
P3 Health Partners	-6.55%	N/A	-16.40%

Exagen has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

Exagen has higher earnings, but lower revenue than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	2.97	-$19.95M	-$0.81	N/A
P3 Health Partners	$1.46B	0.03	-$147.95M	-$33.00	N/A

Summary

Exagen beats P3 Health Partners on 9 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to LifeMD?

P3 Health Partners (NASDAQ:PIII) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

LifeMD has lower revenue, but higher earnings than P3 Health Partners. LifeMD is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.03	-$147.95M	-$33.00	N/A
LifeMD	$194.05M	0.68	$14.35M	-$0.05	N/A

In the previous week, P3 Health Partners' average media sentiment score of 0.00 equaled LifeMD'saverage media sentiment score.

Company	Overall Sentiment
P3 Health Partners	Neutral
LifeMD	Neutral

P3 Health Partners has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, LifeMD has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market.

P3 Health Partners currently has a consensus target price of $17.00, suggesting a potential upside of 167.30%. LifeMD has a consensus target price of $7.57, suggesting a potential upside of 176.33%. Given LifeMD's stronger consensus rating and higher probable upside, analysts plainly believe LifeMD is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by company insiders. Comparatively, 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

LifeMD has a net margin of 0.10% compared to P3 Health Partners' net margin of -6.55%. P3 Health Partners' return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
LifeMD	0.10%	-168.23%	-31.27%

Summary

LifeMD beats P3 Health Partners on 10 of the 14 factors compared between the two stocks.

How does P3 Health Partners compare to Joint?

P3 Health Partners (NASDAQ:PIII) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

P3 Health Partners currently has a consensus price target of $17.00, suggesting a potential upside of 167.30%. Given P3 Health Partners' stronger consensus rating and higher probable upside, equities research analysts plainly believe P3 Health Partners is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 76.9% of Joint shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by insiders. Comparatively, 30.2% of Joint shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

P3 Health Partners has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, Joint has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

In the previous week, Joint had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for Joint and 0 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.00 equaled Joint'saverage media sentiment score.

Company	Overall Sentiment
P3 Health Partners	Neutral
Joint	Neutral

Joint has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.03	-$147.95M	-$33.00	N/A
Joint	$54.90M	1.88	$2.91M	$0.27	26.96

Joint has a net margin of 6.49% compared to P3 Health Partners' net margin of -6.55%. Joint's return on equity of 12.02% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
Joint	6.49%	12.02%	3.47%

Summary

Joint beats P3 Health Partners on 10 of the 15 factors compared between the two stocks.

How does P3 Health Partners compare to Park Dental Partners?

P3 Health Partners (NASDAQ:PIII) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Park Dental Partners had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for Park Dental Partners and 0 mentions for P3 Health Partners. Park Dental Partners' average media sentiment score of 1.47 beat P3 Health Partners' score of 0.00 indicating that Park Dental Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
P3 Health Partners	Neutral
Park Dental Partners	Positive

Park Dental Partners has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.03	-$147.95M	-$33.00	N/A
Park Dental Partners	$244.49M	0.39	-$360K	$1.05	18.90

7.8% of P3 Health Partners shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by company insiders. Comparatively, 10.6% of Park Dental Partners shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

P3 Health Partners currently has a consensus target price of $17.00, indicating a potential upside of 167.30%. Park Dental Partners has a consensus target price of $28.50, indicating a potential upside of 43.65%. Given P3 Health Partners' higher possible upside, equities research analysts clearly believe P3 Health Partners is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Park Dental Partners has a net margin of 0.00% compared to P3 Health Partners' net margin of -6.55%.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
Park Dental Partners	N/A	N/A	N/A

Summary

Park Dental Partners beats P3 Health Partners on 10 of the 14 factors compared between the two stocks.

How does P3 Health Partners compare to Accendra Health?

P3 Health Partners (NASDAQ:PIII) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

P3 Health Partners presently has a consensus price target of $17.00, indicating a potential upside of 167.30%. Accendra Health has a consensus price target of $1.50, indicating a potential upside of 197.38%. Given Accendra Health's higher probable upside, analysts plainly believe Accendra Health is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

7.8% of P3 Health Partners shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by company insiders. Comparatively, 2.3% of Accendra Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

P3 Health Partners has a net margin of -6.55% compared to Accendra Health's net margin of -11.41%. P3 Health Partners' return on equity of 0.00% beat Accendra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
Accendra Health	-11.41%	-4.02%	0.70%

P3 Health Partners has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

In the previous week, Accendra Health had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 1 mentions for Accendra Health and 0 mentions for P3 Health Partners. Accendra Health's average media sentiment score of 0.90 beat P3 Health Partners' score of 0.00 indicating that Accendra Health is being referred to more favorably in the news media.

Company	Overall Sentiment
P3 Health Partners	Neutral
Accendra Health	Positive

P3 Health Partners has higher earnings, but lower revenue than Accendra Health. P3 Health Partners is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.03	-$147.95M	-$33.00	N/A
Accendra Health	$2.73B	0.01	-$1.10B	-$3.91	N/A

Summary

P3 Health Partners beats Accendra Health on 9 of the 16 factors compared between the two stocks.

Get P3 Health Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PIII vs. The Competition

Export

Metric	P3 Health Partners	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$46.18M	$9.59B	$7.14B	$13.18B
Dividend Yield	N/A	2.61%	2.53%	16.78%
P/E Ratio	-0.19	34.21	275.97	26.04
Price / Sales	0.03	5.44	669.23	109.59
Price / Cash	N/A	120.59	77.60	51.75
Price / Book	-0.30	5.15	10.93	6.31
Net Income	-$147.95M	$315.68M	$3.51B	$362.16M
7 Day Performance	-9.79%	-2.59%	-2.00%	-1.66%
1 Month Performance	-30.34%	-3.19%	-6.15%	-4.50%
1 Year Performance	-26.47%	7.93%	7.44%	2.06%

P3 Health Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PIII P3 Health Partners	1.9984 of 5 stars	$6.36 +1.4%	$17.00 +167.3%	-26.1%	$46.18M	$1.50B	N/A	320	Gap Up
XGN Exagen	2.8934 of 5 stars	$8.74 +1.4%	$9.63 +10.1%	-25.0%	$208.82M	$66.57M	N/A	220
LFMD LifeMD	3.1788 of 5 stars	$3.30 +2.5%	$7.57 +129.4%	-60.4%	$155.45M	$194.05M	N/A	384	News Coverage
JYNT Joint	1.4365 of 5 stars	$8.38 -1.3%	N/A	-21.7%	$120.07M	$54.90M	31.04	330
PARK Park Dental Partners	4.1016 of 5 stars	$20.30 -1.9%	$28.50 +40.4%	N/A	$98.39M	$244.49M	19.33	1,212	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PIII) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

P3 Health Partners (PIII) Competitors

PIII vs. XGN, LFMD, JYNT, PARK, and ACH

How does P3 Health Partners compare to Exagen?

Summary

How does P3 Health Partners compare to LifeMD?

Summary

How does P3 Health Partners compare to Joint?

Summary

How does P3 Health Partners compare to Park Dental Partners?

Summary

How does P3 Health Partners compare to Accendra Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

P3 Health Partners (PIII) Competitors

PIII vs. XGN, LFMD, JYNT, PARK, and ACH

How does P3 Health Partners compare to Exagen?

Does the media refer more to XGN or PIII?

Do insiders & institutionals hold more shares of XGN or PIII?

Do analysts recommend XGN or PIII?

Is XGN or PIII more profitable?

Which has more risk & volatility, XGN or PIII?

Which has better valuation & earnings, XGN or PIII?

Summary

How does P3 Health Partners compare to LifeMD?

Which has better valuation & earnings, PIII or LFMD?

Does the media favor PIII or LFMD?

Which has more risk and volatility, PIII or LFMD?

Do analysts prefer PIII or LFMD?

Do insiders and institutionals have more ownership in PIII or LFMD?

Is PIII or LFMD more profitable?

Summary

How does P3 Health Partners compare to Joint?

Do analysts rate PIII or JYNT?

Do insiders & institutionals have more ownership in PIII or JYNT?

Which has more volatility & risk, PIII or JYNT?

Does the media prefer PIII or JYNT?

Which has better earnings & valuation, PIII or JYNT?

Is PIII or JYNT more profitable?

Summary

How does P3 Health Partners compare to Park Dental Partners?

Does the media prefer PIII or PARK?

Which has preferable valuation and earnings, PIII or PARK?

Do insiders and institutionals believe in PIII or PARK?

Do analysts rate PIII or PARK?

Is PIII or PARK more profitable?

Summary

How does P3 Health Partners compare to Accendra Health?

Do analysts rate PIII or ACH?

Do insiders & institutionals believe in PIII or ACH?

Is PIII or ACH more profitable?

Which has more risk and volatility, PIII or ACH?

Does the media favor PIII or ACH?

Which has stronger earnings & valuation, PIII or ACH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools